{"id":"imiquimod-5-manufactured-by-apotex","safety":{"commonSideEffects":[{"rate":"40–90","effect":"Local skin irritation (erythema, erosion, excoriation)"},{"rate":"20–50","effect":"Pruritus"},{"rate":"20–40","effect":"Burning sensation"},{"rate":"20–50","effect":"Scabbing/crusting"},{"rate":"5–15","effect":"Systemic flu-like symptoms (fatigue, fever, myalgia)"},{"rate":"5–10","effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod binds to TLR7 on immune cells, triggering the production of interferon-alpha and other cytokines that enhance local immune activation. This stimulates both innate and adaptive immune responses against abnormal cells or viral-infected cells in the skin. The resulting inflammation and immune cell infiltration lead to clearance of targeted lesions.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:39.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma (superficial and nodular)"},{"name":"Genital warts (external)"},{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"}]},"trialDetails":[{"nctId":"NCT00859105","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis","status":"COMPLETED","sponsor":"Apotex Inc.","startDate":"2008-02","conditions":"Actinic Keratosis","enrollment":497}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Imiquimod 5%: manufactured by Apotex","genericName":"Imiquimod 5%: manufactured by Apotex","companyName":"Apotex Inc.","companyId":"apotex-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers. Used for Actinic keratosis, Basal cell carcinoma (superficial and nodular), Genital warts (external).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}